CA3243870A1 - NLRP3 INHIBITORS - Google Patents

NLRP3 INHIBITORS

Info

Publication number
CA3243870A1
CA3243870A1 CA3243870A CA3243870A CA3243870A1 CA 3243870 A1 CA3243870 A1 CA 3243870A1 CA 3243870 A CA3243870 A CA 3243870A CA 3243870 A CA3243870 A CA 3243870A CA 3243870 A1 CA3243870 A1 CA 3243870A1
Authority
CA
Canada
Prior art keywords
triazin
phenyl
amino
imidazo
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243870A
Other languages
English (en)
French (fr)
Inventor
Xiaoyan Zhang
Rauful Alam
Lauren Bejcek
Bradley B. GILBERT
Seyedmorteza Hosseyni
Eduardo Huarte
Jing Li
Yao Liu
Kyle Niederer
Erica N. Parker
Meenu Pillai
Ettore Rastelli
Nadiya Sydorenko
Nanjing Zhang
Tianyi ZHENG
Matthew G. Woll
Handoko -
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/075421 external-priority patent/WO2023028534A1/en
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of CA3243870A1 publication Critical patent/CA3243870A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3243870A 2022-02-18 2023-02-16 NLRP3 INHIBITORS Pending CA3243870A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263311463P 2022-02-18 2022-02-18
US63/311,463 2022-02-18
PCT/US2022/075421 WO2023028534A1 (en) 2021-08-25 2022-08-24 Inhibitors of nlrp3
USPCT/US2022/075421 2022-08-24
PCT/US2023/062771 WO2023159148A2 (en) 2022-02-18 2023-02-16 Inhibitors of nlrp3

Publications (1)

Publication Number Publication Date
CA3243870A1 true CA3243870A1 (en) 2023-08-24

Family

ID=87579158

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243870A Pending CA3243870A1 (en) 2022-02-18 2023-02-16 NLRP3 INHIBITORS

Country Status (14)

Country Link
US (1) US20250179078A1 (enExample)
EP (1) EP4479045A4 (enExample)
JP (1) JP2025509088A (enExample)
KR (1) KR20240164495A (enExample)
CN (2) CN118302417A (enExample)
AU (1) AU2023221847A1 (enExample)
CA (1) CA3243870A1 (enExample)
CL (1) CL2024002455A1 (enExample)
CO (1) CO2024011162A2 (enExample)
CR (1) CR20240345A (enExample)
IL (1) IL315027A (enExample)
MX (1) MX2024010092A (enExample)
PE (1) PE20250604A1 (enExample)
WO (1) WO2023159148A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
JP2024529839A (ja) * 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
JP2025524640A (ja) * 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
JP2026508178A (ja) 2023-02-14 2026-03-10 シェンチェン ジョンジー バイオロジカル テクノロジー カンパニー， リミテッド Ｎｌｒｐ３を阻害する化合物及びその製造方法と応用
TW202535370A (zh) * 2023-12-14 2025-09-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之吲唑衍生物
WO2025133307A1 (en) * 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
WO2026057747A1 (en) 2024-09-11 2026-03-19 Ac Immune Sa Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
WO2026067767A1 (zh) * 2024-09-30 2026-04-02 普罗思特(南京)生物科技有限公司 取代的哒嗪衍生物及其应用
WO2026132518A1 (en) 2024-12-20 2026-06-25 Ac Immune Sa Heterocyclic compounds modulating the nlrp3 inflammasome pathway

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104583208B (zh) * 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
WO2014007217A1 (ja) * 2012-07-02 2014-01-09 大鵬薬品工業株式会社 イミダゾオキサジン化合物による抗腫瘍効果増強剤
WO2018221433A1 (ja) * 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
CA3174837A1 (en) * 2020-04-15 2021-10-21 Daniel Oehlrich Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway
JP2024529839A (ja) * 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法

Also Published As

Publication number Publication date
CN119212699A (zh) 2024-12-27
CO2024011162A2 (es) 2024-12-09
WO2023159148A3 (en) 2023-10-05
AU2023221847A1 (en) 2024-09-05
CN118302417A (zh) 2024-07-05
US20250179078A1 (en) 2025-06-05
PE20250604A1 (es) 2025-02-26
WO2023159148A2 (en) 2023-08-24
MX2024010092A (es) 2024-12-06
CR20240345A (es) 2024-09-16
IL315027A (en) 2024-10-01
EP4479045A2 (en) 2024-12-25
EP4479045A4 (en) 2026-03-04
JP2025509088A (ja) 2025-04-11
CL2024002455A1 (es) 2025-01-17
KR20240164495A (ko) 2024-11-19

Similar Documents

Publication Publication Date Title
US20250179078A1 (en) Inhibitors of nlrp3
AU2022334474A1 (en) Inhibitors of nlrp3
AU2016304408B2 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
AU2020348675B2 (en) Azole-fused pyridazin-3(2H)-one derivatives
AU2017382029B2 (en) Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-kinase inhibitors
AU2020350745A1 (en) Fused pyridone compound, and preparation method therefor and use thereof
WO2022266258A1 (en) Compounds and methods for the targeted degradation of irak-4
MX2013005603A (es) Derivados de pirrolopiridina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
CA3075751A1 (en) Pyrazolopyrimidinone compounds and uses thereof
JP2025081322A (ja) オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
AU2018271876B2 (en) Pyrazole MAGL inhibitors
JP2024540080A (ja) Ｉｒａｋ４分解剤およびその合成
CA3025636A1 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
AU2018290511B2 (en) Dihydropyrimidine compounds and uses thereof in medicine
AU2010214101A1 (en) Histamine H3 inverse agonists and antagonists and methods of use thereof
WO2015073767A1 (en) Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors
MX2007007483A (es) Derivados de pirroles biciclicos.
WO2016174079A1 (en) Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
WO2008029825A1 (en) Imidazole derivative
TW202227435A (zh) 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之稠合環嘧啶酮衍生物
TW202435887A (zh) 用於治療疾病或障礙的氫喹唑啉衍生物
TW202140499A (zh) 巨環ｒｉｐ２－激酶抑制劑
JP7688449B2 (ja) ピリジン縮合環系化合物とその製造方法、中間体、組成物及び使用
TW202615012A (zh) 用於抑制甲狀腺刺激激素受體之化合物
WO2018109271A1 (en) New bromodomain inhibitors

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240808

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240809

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240809

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240809

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241025

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241025

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250130

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250211

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250411

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260123

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260123

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260528